Latest Insider Transactions at Laboratory Corp Of America Holdings (LH)
This section provides a real-time view of insider transactions for Laboratory Corp Of America Holdings (LH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LABORATORY CORP OF AMERICA HOLDINGS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LABORATORY CORP OF AMERICA HOLDINGS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2024
|
Megan D. Bailey EVP, Pres, Central Labs & Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
69
-13.66%
|
$14,904
$216.35 P/Share
|
|
Apr 01
2024
|
Megan D. Bailey EVP, Pres, Central Labs & Intl |
BUY
Exercise of conversion of derivative security
|
Direct |
205
+28.87%
|
-
|
|
Apr 01
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
3,500
-46.82%
|
$759,500
$217.29 P/Share
|
|
Mar 28
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,553
-31.75%
|
$767,448
$216.74 P/Share
|
|
Mar 27
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,605
-18.89%
|
$562,680
$216.57 P/Share
|
|
Mar 27
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,158
+30.86%
|
-
|
|
Mar 27
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,061
-15.36%
|
$1,093,176
$216.57 P/Share
|
|
Mar 27
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,556
+25.97%
|
-
|
|
Mar 27
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,079
-30.61%
|
$1,097,064
$216.57 P/Share
|
|
Mar 27
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,556
+41.05%
|
-
|
|
Mar 27
2024
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,799
-25.35%
|
$6,868,584
$216.57 P/Share
|
|
Mar 27
2024
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
72,435
+36.61%
|
-
|
|
Mar 27
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
952
-14.85%
|
$205,632
$216.57 P/Share
|
|
Mar 27
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
BUY
Exercise of conversion of derivative security
|
Direct |
3,012
+31.96%
|
-
|
|
Mar 27
2024
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
894
-16.49%
|
$193,104
$216.57 P/Share
|
|
Mar 27
2024
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,079
+36.23%
|
-
|
|
Mar 27
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,162
-22.43%
|
$466,992
$216.57 P/Share
|
|
Mar 27
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,778
+37.48%
|
-
|
|
Mar 27
2024
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,805
-20.18%
|
$1,901,880
$216.57 P/Share
|
|
Mar 27
2024
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
20,033
+31.47%
|
-
|
|
Mar 27
2024
|
Lance Berberian EVP, Special Advisor, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
3,299
-10.54%
|
$712,584
$216.57 P/Share
|
|
Mar 27
2024
|
Lance Berberian EVP, Special Advisor, Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
7,697
+19.73%
|
-
|
|
Mar 07
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
227
-5.56%
|
$49,486
$218.45 P/Share
|
|
Mar 07
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
5,048
-50.06%
|
$1,100,464
$218.45 P/Share
|
|
Mar 07
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,119
+17.36%
|
$247,923
$117.09 P/Share
|
|
Feb 21
2024
|
Glenn A Eisenberg Executive Vice President |
SELL
Open market or private sale
|
Direct |
34,504
-19.67%
|
$7,452,864
$216.64 P/Share
|
|
Feb 21
2024
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
14,054
+19.48%
|
$2,290,802
$163.63 P/Share
|
|
Feb 21
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Open market or private sale
|
Direct |
500
-12.82%
|
$107,500
$215.49 P/Share
|
|
Feb 13
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
237
-3.01%
|
$53,562
$226.45 P/Share
|
|
Feb 12
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
59
-1.49%
|
$13,393
$227.45 P/Share
|
|
Feb 12
2024
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
215
-0.49%
|
$48,805
$227.45 P/Share
|
|
Feb 12
2024
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,231
-2.27%
|
$279,437
$227.45 P/Share
|
|
Feb 12
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
66
-1.59%
|
$14,982
$227.45 P/Share
|
|
Feb 12
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
126
-1.56%
|
$28,602
$227.45 P/Share
|
|
Feb 12
2024
|
Lance Berberian EVP, Special Advisor, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
87
-0.37%
|
$19,749
$227.45 P/Share
|
|
Feb 12
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
137
-0.64%
|
$31,099
$227.45 P/Share
|
|
Feb 12
2024
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
43
-1.8%
|
$9,761
$227.45 P/Share
|
|
Feb 12
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
87
-1.09%
|
$19,749
$227.45 P/Share
|
|
Feb 11
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
BUY
Exercise of conversion of derivative security
|
Direct |
201
+4.83%
|
-
|
|
Feb 11
2024
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
807
+1.79%
|
-
|
|
Feb 11
2024
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,964
+5.18%
|
-
|
|
Feb 11
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
201
+4.62%
|
-
|
|
Feb 11
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
472
+5.51%
|
-
|
|
Feb 11
2024
|
Lance Berberian EVP, Special Advisor, Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
324
+1.35%
|
-
|
|
Feb 11
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
472
+2.15%
|
-
|
|
Feb 11
2024
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
123
+4.91%
|
-
|
|
Feb 11
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
324
+3.91%
|
-
|
|
Feb 08
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
259
-3.28%
|
$57,498
$222.06 P/Share
|
|
Feb 07
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
119
-1.58%
|
$26,537
$223.71 P/Share
|
|
Feb 07
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
BUY
Exercise of conversion of derivative security
|
Direct |
362
+4.58%
|
-
|